New Drug for Alzheimer Disease Shows Promise in Phase 3 Trial
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer-associated amyloid plaques in the brain
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.